Monday, August 17, 2026
Robert LeBoyer, Senior Vice President, Equity Research Analyst, Biotechnology, Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
2Q26 Reported With Review Of New Strategy and Product Data. Cadrenal reported a 2Q26 loss of $3.3 million, or $(1.14) per share. The company modified its strategy and plans to develop its products through collaborations, out-licensing agreements, and non-dilutive grants to conserve capital resources. On June 30, 2026, cash and cash equivalents were $4.2 million, excluding proceeds from the private placement completed July 1. The private placement raised about $3.0 million, with warrants that could raise another $5.8 million upon exercise.
The Pipeline Has Been Reorganized Into “Three Pillars”. The company has divided the pipeline into products for Cardiac Acute Critical Care, Orphan Diseases, and Post-Operative Care. These divisions emphasize how the products can address important needs before and after cardiac surgery, as well as for patient populations with few options.
Get the Full Report
Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.
